Investigation of non-invasive tests for fibrosis diagnosis and prognostication of events in metabolic dysfunction-associated steatotic liver disease: A prospective study cohort

作者
Marie Louise N. Therkelsen,Liv Eline Hetland,Mikkel Parsberg Werge,Mira Thing,Elias Badal Rashu,Puria Nabilou,Nina Kimer,Anders Ellekaer Junker,Alejandro Mayorca Guiliani,M.A. Karsdal,Diana Julie Leeming,Lise Lotte Gluud
出处
期刊:Annals of Hepatology [Elsevier BV]
卷期号:32 (1): 102251-102251
标识
DOI:10.1016/j.aohep.2026.102251
摘要

INTRODUCTION AND OBJECTIVES: Risk stratification is important in the management of metabolic dysfunction-associated steatotic liver disease (MASLD) to prioritize monitoring and treatment resources. We evaluated whether non-invasive tests (NITs) can predict major adverse liver outcomes (MALOs) and diagnose advanced fibrosis in patients with MASLD. PATIENTS AND METHODS: A prospective cohort of 270 patients with MASLD (median age 56 years; 44% female; 41% type 2 diabetes) was evaluated using nine NITs: FIB-4, LSM, Agile3+, Agile4, FAST, ADAPT, ELF, PROC3, and C1M. Cox proportional hazards models and ROC analyses were used to assess prognostic performance for MALOs and diagnosis of advanced fibrosis, respectively. RESULTS: Over a four-year follow-up period, 25 patients experienced MALOs. All NITs were associated with MALOs, though confidence intervals were wide given the limited number of events. Most NITs demonstrated positive associations with risk (HR range 1.82-5.39; p < 0.05), whereas C1M was inversely associated (HR 0.63, 95% CI 0.49-0.82; p < 0.001), indicating reduced risk. As a secondary objective, we evaluated whether each NIT could diagnose advanced fibrosis. FIB-4 and LSM effectively ruled out advanced fibrosis, while ELF and the Agile scores showed the strongest overall discriminative performance. For confirming advanced fibrosis, ELF (81%/76%) and Agile3+ (85%/79%) achieved the best sensitivity-specificity balance. CONCLUSIONS: Our findings suggest that NITs may hold both diagnostic and prognostic value, helping to identify advanced fibrosis and stratify future risk of MALOs in MASLD which is a clinically heterogenous but clinically relevant outcome. Additional research is needed to evaluate their performance in primary care settings.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Wuuuu完成签到,获得积分10
1秒前
SciGPT的应助被binbin采纳,获得80
1秒前
1秒前
豆子完成签到,获得积分10
1秒前
2秒前
3秒前
3秒前
bertharen发布了新的文献求助10
3秒前
桐桐的应助被王晨采纳,获得10
3秒前
英姑的应助被myz采纳,获得10
4秒前
shuyuan完成签到,获得积分10
5秒前
5秒前
CipherSage的应助被会飞的猪采纳,获得10
5秒前
坦率的尔冬完成签到,获得积分10
6秒前
6秒前
在水一方的应助被yinyinyin采纳,获得10
7秒前
Owen的应助被酷酷酷采纳,获得10
7秒前
Lxx发布了新的文献求助10
7秒前
无极微光的应助被wz采纳,获得20
7秒前
传奇3的应助被形成采纳,获得10
8秒前
嘻嘻哈哈的应助被sukiii采纳,获得10
8秒前
9秒前
沈大大发布了新的文献求助10
9秒前
李健的应助被火星上的长颈鹿采纳,获得10
9秒前
9秒前
leizhengyu发布了新的文献求助10
10秒前
10秒前
yinyinyin完成签到,获得积分10
11秒前
想吃很多都不胖完成签到 ,获得积分10
11秒前
棟糖发布了新的文献求助10
11秒前
在水一方的应助被老大车采纳,获得10
12秒前
12秒前
12秒前
13秒前
饿了能吃饭吗完成签到,获得积分10
13秒前
Nole的应助被青青采纳,获得10
13秒前
庞mou发布了新的文献求助10
13秒前
13秒前
李zh完成签到,获得积分10
14秒前
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8188088
求助须知:如何正确求助?哪些是违规求助? 9575942
关于积分的说明 21844291
捐赠科研通 7785857
什么是DOI,文献DOI怎么找? 3435158
关于科研通互助平台的介绍 2559529
邀请新用户注册赠送积分活动 2482065